NCT02847286 is a Phase 1 clinical trial of Dapivirine Ring-004 in HIV- Prevention, sponsored by International Partnership for Microbicides, Inc..

Who is sponsoring NCT02847286?

NCT02847286 is sponsored by International Partnership for Microbicides, Inc..

What drugs are being tested in NCT02847286?

Interventions in NCT02847286: Dapivirine Ring-004, Dapivirine Ring-004 for 28 days along with clotrimazole, Clotrimazole.

What condition does NCT02847286 study?

NCT02847286 studies HIV- Prevention.

Is NCT02847286 still recruiting?

NCT02847286 is currently completed. Last updated 30 August 2017.

Last reviewed 2017-08-30 · How we verify

NCT02847286

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

To Assess the Drug-drug Interaction Potential Between Dapivirine Vaginal Ring-004, Containing 25 mg of Dapivirine, and Clotrimazole 10 mg/g (1%)

Completed Phase 1 Last updated 30 August 2017

What this trial tests

Phase 1 trial testing Dapivirine Ring-004 in HIV- Prevention in 36 participants. Completed in 28 November 2016.

Timeline

1 September 2015

Primary endpoint
28 November 2016

28 November 2016

Quick facts

Lead sponsor	International Partnership for Microbicides, Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	prevention
Enrollment	36
Start date	1 September 2015
Primary completion	28 November 2016
Estimated completion	28 November 2016

Drugs / interventions tested

Dapivirine Ring-004 — full drug profile →
Dapivirine Ring-004 for 28 days along with clotrimazole — full drug profile →
Clotrimazole (clotrimazole) — full drug profile →

Conditions studied

HIV- Prevention — all drugs for HIV- Prevention →

Sponsor

International Partnership for Microbicides, Inc. — full company profile →

Who can join

Adults 18 to 45, female only, with HIV- Prevention. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Study to assess the drug-drug interaction potential, between Dapivirine Vaginal Ring-004, containing 25 MG of Dapivirine.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other International Partnership for Microbicides, Inc. trials

Trials by the same sponsor.

NCT05416021 — Relative Bioavailability Trial of Dapivirine Ring-004 and Ring-008 · Phase 1 · completed
NCT05041699 — PK, Safety Study of 90-Day Use of Vaginal Rings Containing Dapivirine and Levonorgestrel · Phase 1 · completed
NCT03467347 — PK Study of 90-Day Use of Vaginal Rings Containing Dapivirine and Levonorgestrel · Phase 1 · completed
NCT03234400 — A Phase 1, Randomized Pharmacokinetics and Safety Study of Extended Duration Dapivirine Vaginal Rings · Phase 1 · completed
NCT02855346 — PK and Safety Study of Vaginal Rings Containing Dapivirine and Levonorgestrel · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02847286 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by International Partnership for Microbicides, Inc.
Last refreshed: 30 August 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02847286.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing